Shire files law suit to block Mylan's generic Fosrenol

UK firm Shire has filed a law suit in the US District Court of the Southern District of New York against local firm Mylan to prevent the  generic drugmaker's attempt to market and sell copy versions of its  500mg, 750mg, and 1g strengths of hyperphosphatemia drug Fosrenol  (lanthanum carbonate).

Shire has asserted its '976 patent based upon information provided to it  by Mylan. Shire says it will continue to evaluate the situation  throughout the litigation and will take all necessary actions to protect  its rights to the fullest extent possible. The UK company adds that it  has a robust patent estate and is confident that it will protect the  Fosrenol franchise.